Human Papilloma Virus Detection by INNOLiPA HPV in Prostate Tissue from Men of Northeast Mexico

  • Published : 2016.11.01


Background: Prostatic adenocarcinoma by Prosate cancer (PCa) is the most prevalent cancer and the second cause of cancer-related death among men in the Western world. Human papilloma virus (HPV) may be considered as a preventable risk factor. In this study, we assessed the frequencies of HPV infection in prostatic adenocarcinoma and benign prostatic hyperplasia (BPH) cases in Northeast Mexico. Materials and Methods: A total of 87 paraffin-embedded blocks (from 25 and 62 patients with definite diagnoses of BPH and adenocarcinoma, respectively) were selected and subjected to INNOLiPA HPV Genotyping to detect 28 high- and low-risk HPV types. The rates of infection were compared in the two studied groups. Results: INNOLiPA HPV demonstrated great sensitivity for HPV detection on paraffin-embedded tissue. Global prevalence was 14.9% (13/87). HPV infection was positive in 19.4% (12/62) of patients with adenocarcinoma and 4.0% (1/25) of patients with BPH. HPV-11, which is considered to be low risk, was more prevalent. Interestingly, one patient with BPH and six with prostate cancer showed examples considered to be high risk (HPV-18, -51, -52, and -66). Conclusion: A higher rate of HPV infection among Mexican patients with prostatic carcinoma than among those with BPH was observed. HPV infections may thus contribute to the risk of prostate cancer. Further studies are required to elucidate any roles of HPV infection in prostate disease in Mexico and the effect of prevention and treatment of HPV infection on prostatic adenocarcinoma.


  1. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J (2003). Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 12, 872-5.
  2. Aghakhani A, Hamkar R, Parvin M, et al (2011). The role of Human papillomavirus infection in prostate carcinoma. Scand J Infect Dis, 43, 64-9.
  3. Anwar K, Nakakuki K, Shiraishi T, et al (1992). Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res, 52, 5991-6.
  4. Araujo-Neto AP, Ferreira-Fernandes H, Amaral CM, et al (2016). Lack of detection of human papillomavirus DNA in prostate carcinomas in patients from northeastern Brazil. Genet Mol Biol, 39, 24-9.
  5. Atashafrooz F, Rokhbakhsh-Zamin F (2016). Frequency and type distribution of human papilloma virus in patients with prostate cancer, kerman, southeast of Iran. Asian Pac J Cancer Prev, 17 , 3953-8
  6. Carozzi F, Lombardi FC, Zendron P, et al (2004). Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers, 19, 257-61.
  7. Choo CK, Ling MT, Chan KW, et al (1999). Immortalization of human prostate epithe¬lial cells by HPV 16 E6/E7 open reading frames. Prostate, 40, 150-8.<150::AID-PROS2>3.0.CO;2-7
  8. Dell G, Gaston K (2001). Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci, 58, 1923-42.
  9. Ghasemian E, Monavari SH, Irajian GR, et al (2013). Evaluation of human papillomavirus infections in prostatic disease: a cross-sectional study in Iran. Asian Pac J Cancer Prev, 14, 3305-8.
  10. Hrbacek J, Urban M, Hamsikova E, et al (2011). Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer, 11, 53.
  11. Lazcano-Ponce E (2001). High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. STD, 28, 277-80.
  12. Marklund L, Hammarstedt L (2011). Impact of HPV in oropharyngeal cancer. J Oncol, 10, 509036.
  13. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, et al (2010). Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer, 10, 326-30.
  14. McNicol PJ, Dodd JG (1990). Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol, 28, 409-12.
  15. Medeiros F, Rigl CT, Anderson GG Becker SH, Halling KC (2007). Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med, 131, 1805-16.
  16. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U (1999). Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers.Cancer Res, 59, 823-5.
  17. Sfanos KS, Isaacs WB, De Marzo AM (2013). Infections and inflammation in prostate cancer. Am J Clin Exp Urol, 25, 3-11.
  18. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.
  19. Strickler HD, Burk R, Shah K, et al (1998). A multifaceted study of human papillomavirus and prostate carcinoma. Cancer, 82, 1118-25.<1118::AID-CNCR16>3.0.CO;2-9
  20. Yang L, Xie S, Feng X, et al (2015). Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis. Sci Rep, 5, 14667.